Travere Therapeutics (TVTX) Set to Announce Earnings on Monday

Travere Therapeutics (NASDAQ:TVTX) is scheduled to announce its earnings results after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of ($0.98) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, February 15th. The company reported ($1.16) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.11. The company had revenue of $45.06 million during the quarter, compared to analysts’ expectations of $41.25 million. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%. On average, analysts expect Travere Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Travere Therapeutics Stock Performance

Shares of TVTX stock opened at $6.26 on Friday. The company’s fifty day simple moving average is $7.07 and its two-hundred day simple moving average is $7.60. Travere Therapeutics has a 52 week low of $5.12 and a 52 week high of $19.54. The company has a current ratio of 3.47, a quick ratio of 3.41 and a debt-to-equity ratio of 1.88.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on TVTX shares. HC Wainwright increased their price target on Travere Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Guggenheim reiterated a “neutral” rating on shares of Travere Therapeutics in a research report on Wednesday, March 27th. Piper Sandler boosted their price target on shares of Travere Therapeutics from $10.00 to $11.00 and gave the stock a “neutral” rating in a research report on Thursday, January 18th. Wedbush reiterated an “outperform” rating and set a $13.00 price objective on shares of Travere Therapeutics in a research report on Wednesday, April 17th. Finally, Wells Fargo & Company boosted their target price on shares of Travere Therapeutics from $8.00 to $9.00 and gave the stock an “equal weight” rating in a report on Friday, February 16th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.